|This article does not cite any sources. (December 2009) (Learn how and when to remove this template message)|
|Chemical and physical data|
|Molar mass||39589.6 g/mol|
Reteplase is a recombinant non-glycosylated form of human tissue plasminogen activator, which has been modified to contain 357 of the 527 amino acids of the original protein. It is produced in the bacterium Escherichia coli.
Reteplase is similar to recombinant human tissue plasminogen activator (alteplase), but the modifications give reteplase a longer half-life of 13–16 minutes. Reteplase also binds fibrin with lower affinity than alteplase, improving its ability to penetrate into clots.
Reteplase was approved by the Food and Drug Administration in 1996.
As reteplase is able to penetrate inside the thrombi, an enhanced fibrinolytic activity will be achieved → rapid reperfusion → low incidence of bleeding.
|This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.|